Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
Prozac (fluoxetine hydrochloride) is an oral selective serotonin reuptake inhibitor (SSRI) approved in 1987 for depression, anxiety disorders, OCD, and bulimia. It works by increasing serotonin availability in the central nervous system to improve mood and reduce compulsive behaviors. Fluoxetine is one of the most widely prescribed antidepressants globally and remains a foundational treatment in psychiatry.
Prozac is in advanced lifecycle maturity with moderate competitive pressure (45/100), suggesting a stable but defensive commercial environment with focus on retention and cost-efficiency.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Under Fasting Condition
Fasting Study of Fluoxetine Capsules 40 mg and Prozac Pulvules 40 mg
Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's Under Fed Condition
90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions
90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions
Worked on PROZAC at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Prozac offers stability and deep category expertise in psychiatry but limited growth trajectory; career value lies in managing a legacy franchise, defending against competitors, and navigating generic/biosimilar competitive dynamics. Roles emphasize operational excellence, payer management, and therapeutic area mastery rather than innovation.